دورية أكاديمية
أعرض في EDS

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.

التفاصيل البيبلوغرافية
العنوان: Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
المؤلفون: Surarak T; Faculty of Pharmacy, Mahidol University, Bangkok, Thailand., Chumnumwat S; Faculty of Pharmacy, Mahidol University, Bangkok, Thailand., Nosoongnoen W; Faculty of Pharmacy, Mahidol University, Bangkok, Thailand., Tragulpiankit P; Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
المصدر: Clinical and translational science [Clin Transl Sci] 2024 Apr; Vol. 17 (4), pp. e13795.
نوع المنشور: Systematic Review; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Malden, MA : WileyBlackwell Pub., 2008-
مواضيع طبية MeSH: Antitubercular Agents*/adverse effects , Antitubercular Agents*/pharmacokinetics , Arylamine N-Acetyltransferase*/genetics , Arylamine N-Acetyltransferase*/metabolism , Chemical and Drug Induced Liver Injury*/etiology , Chemical and Drug Induced Liver Injury*/genetics , Isoniazid*/adverse effects , Isoniazid*/pharmacokinetics , Tuberculosis*/drug therapy , Tuberculosis*/genetics, Adult ; Child ; Humans ; Genotype ; Polymorphism, Genetic
مستخلص: N-acetyltransferase 2 (NAT2) genetic polymorphisms might alter isoniazid metabolism leading to toxicity. We reviewed the impact of NAT2 genotype status on the pharmacokinetics, efficacy, and safety of isoniazid, a treatment for tuberculosis (TB). A systematic search for research articles published in Scopus, PubMed, and Embase until August 31, 2023, was conducted without filters or limits on the following search terms and Boolean operators: "isoniazid" AND "NAT2." Studies were selected if NAT2 phenotypes with pharmacokinetics or efficacy or safety of isoniazid in patients with TB were reported. Patient characteristics, NAT2 status, isoniazid pharmacokinetic parameters, early treatment failure, and the prevalence of drug-induced liver injury were extracted. If the data were given as a median, these values were standardized to the mean. Forty-one pharmacokinetics and 53 safety studies were included, but only one efficacy study was identified. The average maximum concentrations of isoniazid were expressed as supratherapeutic concentrations in adults (7.16 ± 4.85 μg/mL) and children (6.43 ± 3.87 μg/mL) in slow acetylators. The mean prevalence of drug-induced liver injury was 36.23 ± 19.84 in slow acetylators, which was significantly different from the intermediate (19.49 ± 18.20) and rapid (20.47 ± 20.68) acetylators. Subgroup analysis by continent showed that the highest mean drug-induced liver injury prevalence was in Asian slow acetylators (42.83 ± 27.61). The incidence of early treatment failure was decreased by genotype-guided isoniazid dosing in one study. Traditional weight-based dosing of isoniazid in most children and adults yielded therapeutic isoniazid levels (except for slow acetylators). Drug-induced liver injury was more commonly observed in slow acetylators. Genotype-guided dosing may prevent early treatment failure.
(© 2024 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
References: Antimicrob Agents Chemother. 2020 Mar 24;64(4):. (PMID: 31964788)
Tuberc Respir Dis (Seoul). 2020 Dec;83(Supple 1):S55-S62. (PMID: 33138342)
Children (Basel). 2022 Jul 29;9(8):. (PMID: 36010027)
PLoS One. 2023 Apr 6;18(4):e0283726. (PMID: 37023111)
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):52-57. (PMID: 30572983)
Clin Ther. 2020 Nov;42(11):e220-e241. (PMID: 33032843)
BMC Infect Dis. 2016 Apr 02;16:144. (PMID: 27039088)
Arch Dis Child. 2005 Jun;90(6):614-8. (PMID: 15908628)
Clin Pharmacol Ther. 1997 Oct;62(4):377-83. (PMID: 9357388)
Toxicol Rep. 2016 Oct 17;3:826-831. (PMID: 28959610)
BMC Genet. 2008 Feb 27;9:21. (PMID: 18304320)
J Antimicrob Chemother. 2016 May;71(5):1323-9. (PMID: 26832752)
Mol Biol Rep. 2013 May;40(5):3591-6. (PMID: 23277397)
Tuberculosis (Edinb). 2021 Mar;127:102052. (PMID: 33548864)
ChemMedChem. 2017 Oct 20;12(20):1657-1676. (PMID: 28921911)
Toxicol Sci. 2004 Nov;82(1):318-32. (PMID: 15282401)
Hepatology. 2011 Oct;54(4):1344-50. (PMID: 21735470)
Tuberculosis (Edinb). 2022 Sep;136:102246. (PMID: 35961094)
Int J Clin Pharmacol Ther. 2014 Apr;52(4):292-302. (PMID: 24447650)
Pharmacogenomics J. 2021 Aug;21(4):467-475. (PMID: 33649521)
Clin Pharmacol Ther. 2021 Apr;109(4):1125-1135. (PMID: 33135175)
Antimicrob Agents Chemother. 2020 Dec 16;65(1):. (PMID: 33139294)
J Antimicrob Chemother. 2014 Oct;69(10):2841-7. (PMID: 25140577)
Pharmacogenomics J. 2017 Jul;17(4):372-377. (PMID: 27089936)
J Clin Transl Res. 2018 May 28;4(1):75-100. (PMID: 30873497)
Ther Drug Monit. 2019 Oct;41(5):648-656. (PMID: 30939588)
BMC Med Res Methodol. 2014 Dec 19;14:135. (PMID: 25524443)
Int J Infect Dis. 2021 Mar;104:562-567. (PMID: 33476758)
Clin Transl Sci. 2024 Apr;17(4):e13795. (PMID: 38629592)
Toxicol Sci. 2002 Apr;66(2):185-200. (PMID: 11896285)
J Clin Pharm Ther. 2020 Jun;45(3):503-512. (PMID: 31833581)
Pharmacogenetics. 1993 Oct;3(5):264-9. (PMID: 8287065)
BMC Infect Dis. 2015 Mar 14;15:126. (PMID: 25887748)
Int J Infect Dis. 2022 Sep;122:725-732. (PMID: 35868608)
In Vivo. 2011 Sep-Oct;25(5):803-12. (PMID: 21753138)
Pharmacogenet Genomics. 2013 Apr;23(4):200-7. (PMID: 23407048)
J Infect Dis. 2013 Nov 1;208(9):1464-73. (PMID: 23901086)
Tuberculosis (Edinb). 2019 May;116S:S66-S70. (PMID: 31076322)
Clin Pharmacol Ther. 2011 Jun;89(6):806-15. (PMID: 21544079)
Biochem J. 2019 Jul 18;476(14):1995-2016. (PMID: 31320388)
Pharmacogenomics. 2015 Dec;16(18):2083-97. (PMID: 26616266)
Pharmacogenomics. 2014 Feb;15(3):285-96. (PMID: 24533708)
Eur J Clin Pharmacol. 2022 Oct;78(10):1535-1553. (PMID: 35852584)
Eur J Clin Pharmacol. 2007 Jul;63(7):633-9. (PMID: 17505821)
Eur J Clin Pharmacol. 2013 May;69(5):1091-101. (PMID: 23150149)
المشرفين على المادة: 0 (Antitubercular Agents)
EC 2.3.1.5 (Arylamine N-Acetyltransferase)
V83O1VOZ8L (Isoniazid)
EC 2.3.1.5 (NAT2 protein, human)
تواريخ الأحداث: Date Created: 20240417 Date Completed: 20240418 Latest Revision: 20240501
رمز التحديث: 20240501
مُعرف محوري في PubMed: PMC11022300
DOI: 10.1111/cts.13795
PMID: 38629592
قاعدة البيانات: MEDLINE
الوصف
تدمد:1752-8062
DOI:10.1111/cts.13795